Rhinitis
Conditions
Interventions
Control group:Normal saline
Group 1:Birofen
Group 2:Nasal hormone
Group 3:Birofen and nasal hormones
Sponsors
Renmin Hospital of Wuhan University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-60 years; 2. Patients who meet any of the following criteria: (1) Patients diagnosed with CRSwNP according to the diagnostic criteria recommended in the European Position Paper on Sinusitis and nasal polyps, or double-positive ECP-MPO nasal discharge strips; (2) Patients with allergic rhinitis (according to ARIA criteria), skin prick test or serum specific IgE level 3 or above, or ECP-MPO nasal discharge strip ECP-positive; (3) Patients who meet the diagnosis of vasomotor rhinitis and the ECP-MPO nasal discharge test paper is completely negative; (4) Patients who meet the diagnosis of simple rhinitis and the ECP-MPO nasal discharge test paper is completely negative; 3. The patient agrees to participate in the experiment and signs the informed consent; 4. Patients judged by the investigator to meet the requirements of the protocol.
Exclusion criteria
Exclusion criteria: 1. Patients with nasal mucosa erosion, nasal mucosa ulcer and nasal septum perforation were found through nasal examination; 2. Patients receiving anticoagulant drugs within 5 days; 3. Nasal surgery within a month; 4. Patients with other nasal diseases that may lead to drug deposition in the nasal cavity, such as sinusitis, drug-induced rhinitis, nasal polyps or nasal structural abnormalities; 5. Patients with non-allergic rhinitis (vasomotor rhinitis, eosinophilic rhinitis); 6. Patients who received nasal surgery within 90 days before the start of the observation period were screened; 7. Patients with contraindications to desensitization; 8. Patients with recurrent nasal bleeding; 9. Patients suffering from complications such as severe liver disease, kidney disease, heart disease or blood disease; 10. The presence of alcohol or drug abuse/addiction may affect the progress of the study. Binge drinking is defined as having more than 14 units of alcohol per week (1 unit of alcohol =360 mL beer, 45 mL spirits at 40% alcohol or 150mL wine); 11. Systemic or topical use of antibiotics, intranasal hormones, intranasal or oral antihistamines within 1 week prior to sampling, systemic use of corticosteroids or immunosuppressants 3 weeks prior to sampling; 12. Upper respiratory tract infection or other acute infection within 30 days; 13. Patients judged by the investigator to be unsuitable subjects for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptom score; | — |
Countries
China
Contacts
Public ContactDeng Yuqin
Outcome results
None listed